- Thinly traded nano cap MabVax Therapeutics Holdings (OTCQB:MBVX) is up 22% premarket on light volume in response to its announcement of preliminary results from a Phase 1 clinical trial evaluating the safety of radioimmunotherapy candidate MVT-1075 in patients with CA19-9-positive cancers.
- Data from the first three patients in the dose-escalation phase showed MVT-1075 was "reasonably well-tolerated" and accumulated on tumor cells after the first dose. Blood-related toxicities were manageable. Two of the three subjects met the criteria for stable disease.
- Enrollment in the second cohort at the next higher dose is underway.
- MVT-1075 is a targeted cancer therapy that utilizes a fully human monoclonal antibody, HuMab-5B1, to deliver a cytotoxic payload, the radioisotope Lutetium-177, to cancer cells expressing the CA19-9 protein.
- Previously: MabVax completes enrollment in first cohort in early-stage study of cancer candidate MVT-1075; shares up 4% (Dec. 13, 2017)
- Now read: Your Daily Pharma Scoop: A Look At Celldex, BeiGene Data, Axovant Announces Changes At Top
Original article